We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

ADI-PEG in Patients With Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00029900
Recruitment Status : Completed
First Posted : January 25, 2002
Last Update Posted : March 25, 2015
Information provided by:
FDA Office of Orphan Products Development

Brief Summary:
This is a study to determine the safety and toxicity of increasing doses of arginine deiminase combined to polyethylene glycol (ADI-PEG) in patients with nonresectable metastatic melanoma.

Condition or disease Intervention/treatment Phase
Melanoma Neoplasm Metastasis Drug: ADI PEG Phase 1

Detailed Description:

The use of amino acid degrading enzymes derived from microbial sources has proven to be an effective means of controlling some forms of cancer auxotrophic for nonessential amino acids. Recently it has been shown that human melanomas are auxotrophic for arginine. As arginine is a nonessential amino acid for humans, elimination of it may prove to be an effective method for controlling cancer. Laboratory studies have provided promising results with the arginine-degrading enzyme arginine deiminase (ADI) coupled to polyethylene glycol (PEG) to enhance its circulating half-life.

In this study, patients each receive 3 intramuscular treatments of ADI-SS PEG over a 4-week period. There are 4 cohorts of patients each receiving a different dose level. Pharmacokinetics, pharmacodynamics, safety and toxicity, and immunogenicity studies will be performed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 15 participants
Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Testing of ADI-PEG in Metastatic Melanoma
Study Start Date : September 2001
Study Completion Date : August 2003

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Histologically confirmed metastatic melanoma
  • Nonresectable disease
  • Measurable or evaluable disease
  • Progressive disease following standard chemotherapy, radiotherapy, surgery, or immunotherapy; and no longer responding to therapy
  • Recovered from prior surgery
  • Karnofsky performance status 70 or higher
  • Expected survival of at least 12 weeks
  • Bilirubin less than 2.0 mg/dL
  • Albumin greater than 3.0 g/dL
  • SGOT less than 5 times upper limit of normal (ULN)
  • Alkaline phosphatase less than 5 times ULN
  • Ammonia less than 55 microg/dL
  • Glucose greater than 60 mg/dL
  • Amylase less than 1.5 times ULN
  • Absolute neutrophil count greater than 1,500/mm3
  • Platelet count greater than 100,000/mm3
  • Patients must use 2 forms of effective contraception

Exclusion criteria:

  • Prior therapy within the past 4 weeks
  • Ascites or pleural effusion
  • Significant cardiac disease (i.e., New York Heart Association class III or IV heart disease)
  • Pregnant or nursing
  • Concurrent enrollment in another IND study
  • Serious infection requiring antibiotics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00029900

Layout table for location information
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
FDA Office of Orphan Products Development
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00029900    
Other Study ID Numbers: FD-R-2003-01
First Posted: January 25, 2002    Key Record Dates
Last Update Posted: March 25, 2015
Last Verified: January 2002
Keywords provided by FDA Office of Orphan Products Development:
Dose-Response Relationship, Drug
Polyethylene Glycol
Arginine Deiminase
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplastic Processes
Pathologic Processes